

ARROW THERAPEUTICS

Leading novel antiviral drug discovery and development



about arrow

Founded in 1998 and acquired by AstraZeneca in February 2007, Arrow Therapeutics is a fully integrated pharmaceutical company focused exclusively on the discovery and development of anti-infective therapeutics. We specialise in small molecule drugs with novel mechanisms of action that will address the urgent unmet medical needs in the antiviral field.

Based in central London, Arrow is a resourceful company with over 50 people employed across various scientific disciplines. It has always been our belief that having biology, chemistry, preclinical and clinical development departments within one building will lead to more effective drug discovery. The result is an integrated approach ranging from novel target identification through to Phase II clinical development.

Our in-house research efforts have resulted in compounds against Respiratory Syncytial Virus and Hepatitis C.

With our research approach well established we are now stepping up our development activities. The leading RSV compound is currently in Phase II trials in the US, Europe and Australia in adult patients infected with RSV after stem cell transplantation. This programme was partnered with Novartis in June 2005 in a deal worth up to \$217 million in milestone payments, plus royalties.

Our Hepatitis C programme consists of multiple series from different chemical classes. The most advanced compounds inhibit NS5a, a novel viral target. The lead compound A-831 entered Phase I trials in Q4 2006. A second compound A-689, of completely different chemical structure but also targeting NS5a, entered preclinical development in Q1 2007. Arrow also has a Hepatitis C polymerase programme in lead optimisation.



product pipeline



company history

1998 - Arrow established by 6 founding scientists, based in laboratories in Surrey. Seed funding provided by Unibio and founding scientists.

1999 - Private shareholder funding round raises £1.5 million.

2000 - Series A venture capital funding round raises £11.1 million.

2001 - Arrow moves to state-of-the-art laboratories and office space in central London.

2002 - Series A venture capital funding round raises a further £7 million.

2003 - Arrow's RSV compound enters Preclinical development.

2004 - Series B venture capital funding round raises over £23 million.

2004 - Arrow's RSV compound completes Phase I trials.

2005 - Arrow's RSV compound enters Phase II trials.

2005 - Arrow's RSV compound licensed to Novartis.

2006 - Arrow selects Hepatitis C clinical candidate A-831.

2006 - Arrow's HCV compound A-831 enters Phase I.

2007 - Arrow selects further Hepatitis C clinical candidate A-689.

2007 - AstraZeneca acquires Arrow to broaden Anti-infective capabilities.

February 2007 - AstraZeneca Acquires Arrow Therapeutics to Broaden Anti-Infective Capabilities

On 1st February 2007 AstraZeneca announced an agreement to acquire Arrow, with the total share capital of Arrow to be purchased for \$150m cash.

January 2007 - Arrow Therapeutics selects further HCV clinical candidate

In January 2007 Arrow announced that a further Hepatitis C compound, A-689, has entered full preclinical development.

December 2006 - Arrow Therapeutics adds CMO to Senior Management Team

In December 2006 Arrow announced that it has appointed Dereck Tait, previously of Idenix Pharmaceuticals, as Chief Medical Officer.

November 2006 - Arrow Therapeutics HCV compound enters Phase I

In November 2006 Arrow announced that it has initiated a Phase I study of A-831, a small molecule antiviral inhibitor of Hepatitis C infection.



recent news

Management Team

Head of Arrow

Ken Powell

Research Director

Stuart Cockerill

Director of Development

& Legal

Sue Grieve

Chief Medical Officer

Dereck Tait

Arrow Therapeutics Ltd
Britannia House
7 Trinity Street
London SE1 1DB UK

Tel: +44 (0)207 015 1000
Fax: +44 (0)207 015 1020
info@arrowt.co.uk
www.arrowt.co.uk